All Releases
 |
OrthoLogic Announces Positive Safety Data for Initial AZX100 Phase 1 Human Clinical Trial in Dermal/Hypertrophic Scarring
May 8, 2008
|
9.4 KB |
| |
TEMPE, Ariz., May 8, 2008 (PrimeNewswire via COMTEX News Network) -- OrthoLogic Corp. (Nasdaq:OLGC) announced today the completion of dosing and patient follow-up for its initial AZX100 Phase 1 human clinical trial in dermal/hypertrophic scarring.
The Safety Committee reviewing all safety-related aspects of the clinical trial was satisfied with...
|
|
OrthoLogic Announces First Quarter 2008 Financial Results and Conference Call
May 7, 2008
|
13.1 KB |
| |
TEMPE, Ariz., May 7, 2008 (PrimeNewswire via COMTEX News Network) -- OrthoLogic Corp. (Nasdaq:OLGC) today announced financial results for the first quarter of 2008.
OrthoLogic reported a net loss of $2.7 million, or $0.06 per share, for the first quarter of 2008, compared to a net loss of $2.9 million or $0.07 per share for the first quarter of...
|
|
OrthoLogic Announces Year End 2007 Operating Results and Stock Repurchase Program
Mar 5, 2008
|
18.1 KB |
| |
TEMPE, Ariz., Mar 5, 2008 (PrimeNewswire via COMTEX News Network) -- OrthoLogic Corp. (Nasdaq:OLGC) today announced operating results for the year ended December 31, 2007. The Company also announced that its Board of Directors has approved a stock repurchase program for up to five percent of its currently outstanding common shares. The shares may b...
|
|
OrthoLogic Announces Initiation of Dosing for AZX100 Phase 1 Human Clinical Trial in Dermal/Hypertrophic Scarring
Feb 29, 2008
|
8.9 KB |
| |
TEMPE, Ariz., Feb 29, 2008 (PrimeNewswire via COMTEX News Network) -- OrthoLogic Corp. (Nasdaq:OLGC) announced today the initiation of dosing for its AZX100 Phase 1 human clinical trial in dermal/hypertrophic scarring.
The clinical study is a first-in-man Phase 1, randomized, placebo controlled, dose-escalation, single center study in which the...
|
|
OrthoLogic to Host Conference Call Discussing Year-End 2007 Financial Results
Feb 27, 2008
|
8.2 KB |
| |
TEMPE, Ariz., Feb 27, 2008 (PrimeNewswire via COMTEX News Network) -- OrthoLogic Corp. (Nasdaq:OLGC) announced today that it will release financial and operating results for the year ending December 31, 2007 on Wednesday, March 5, 2008.
Management will host a conference call and webcast on Wednesday, March 5, 2008 at 1:30 pm PST / 2:30 pm MST /...
|
|
Orthologic Announces FDA Acceptance of AZX100 IND Application in Dermal/Hypertrophic Scarring; Phase 1 Human Clinical Trial to Begin 1Q2008
Jan 28, 2008
|
9.2 KB |
| |
TEMPE, Ariz., Jan 28, 2008 (PrimeNewswire via COMTEX News Network) -- OrthoLogic Corp. (Nasdaq:OLGC) announced today that the U.S. Food and Drug Administration (FDA) has accepted an investigational new drug (IND) application for AZX100 in dermal/hypertrophic scarring. Phase 1 human clinical trials will begin during 1Q2008.
The clinical study wi...
|
|
OrthoLogic Announces Third Quarter 2007 Financial Results
Nov 5, 2007
|
13.8 KB |
| |
TEMPE, Ariz., Nov 5, 2007 (PrimeNewswire via COMTEX News Network) -- OrthoLogic Corp. (Nasdaq:OLGC) today announced financial results for the third quarter 2007.
OrthoLogic reported a net loss of $2.4 million, or $0.06 per share, for the third quarter 2007, compared to a net loss of $5.8 million or $0.14 per share for the third quarter 2006. Fo...
|
|
OrthoLogic to Host Conference Call Discussing Third Quarter 2007 Results
Oct 31, 2007
|
7.7 KB |
| |
TEMPE, Ariz., Oct 31, 2007 (PrimeNewswire via COMTEX News Network) -- OrthoLogic Corp. (Nasdaq:OLGC) announced today that it will release financial and operating results for the third quarter ending September 30, 2007 on Tuesday, November 6, 2007.
Management will host a conference call and webcast on Tuesday, November 6, 2007 at 6:30 am MST (8:...
|
|
Orthologic to Present At the Bio Investor Forum 2007 October 10, 2007 -- San Francisco, CA
Oct 5, 2007
|
7.1 KB |
| |
TEMPE, Ariz., Oct 5, 2007 (PrimeNewswire via COMTEX News Network) -- OrthoLogic Corp. (Nasdaq:OLGC) today announced that Dana B. Shinbaum, Vice President, Business Development, will present a corporate overview at the BIO Investor Forum 2007. The presentation is scheduled for Wednesday, October 10, 2007 at 10:15 a.m. PDT. The event is being held at...
|
|
OrthoLogic to Present At the Wall Street Analyst Forum September 20, 2007 -- New York, NY
Sep 17, 2007
|
7.8 KB |
| |
TEMPE, Ariz., Sep 17, 2007 (PrimeNewswire via COMTEX News Network) -- OrthoLogic Corp. (Nasdaq:OLGC) today announced that Dana B. Shinbaum, Vice President, Business Development, will present a corporate overview at the Wall Street Analyst Forum. The presentation is scheduled for 12:40 PM (Eastern Time) on Thursday, September 20, 2007. The event is ...
|
|
OrthoLogic To Present At The First Albany Capital Regenerative Technologies Conference
Sep 6, 2007
|
6.3 KB |
| |
TEMPE, AZ - September 6, 2007 - OrthoLogic Corp. (NASDAQ: OLGC) today announced that Executive Chairman Jock Holliman will present a corporate overview at the First Albany Capital Regenerative Technologies Conference. The presentation is scheduled for 3:40 PM (Eastern Time) on September 11, 2007. The event is being held at The Yale Club of N...
|
|
OrthoLogic Announces Second Quarter 2007 Financial Results
Aug 8, 2007
|
20.2 KB |
| |
TEMPE, AZ - August 8, 2007 - OrthoLogic Corp. (NASDAQ: OLGC) today announced financial
results for the second quarter 2007.OrthoLogic reported a net loss of $2.3 million, or $0.06 per share, for the second quarter 2007,
compared to a net loss of $6.5 million or $0.16 per share for the second quarter 2006. For the six
months en...
|
|
OrthoLogic Establishes Scientific Advisory Board
Aug 2, 2007
|
11.2 KB |
| |
TEMPE, AZ – AUGUST 2, 2007 – OrthoLogic Corp. (NASDAQ: OLGC) today announced the formation of a Scientific Advisory Board (SAB) with the appointments of Michael E. Mendelsohn, M.D. of Tufts-New England Medical Center and Charles A. Dinarello, M.D. of University of Colorado School of Medicine. The SAB will provide independent scientific ...
|
|
OrthoLogic Announces First Quarter 2007 Financial Results
May 7, 2007
|
15.1 KB |
| |
TEMPE, Ariz., May 7, 2007 (PRIME NEWSWIRE) -- OrthoLogic Corp. (Nasdaq:OLGC) today announced financial results for the first quarter of 2007.
OrthoLogic reported a net loss of $2.9 million, or $0.07 per share, for the first quarter of 2007, compared to a net loss of $16.5 million or $0.42 per share, for the first quarter of 2006. The...
|
|
OrthoLogic Announces Year End 2006 Financial Results
Mar 14, 2007
|
20.2 KB |
| |
TEMPE, Ariz., Mar 14, 2007 (PrimeNewswire via COMTEX News Network) -- OrthoLogic Corp. (Nasdaq:OLGC) today announced financial results for the year ending December 31, 2006. Net loss was $31.9 million, or $0.78 per share versus a net loss of $27.2 million or $0.72 per share for the year ended December 31, 2005. The $4.7 million increase in net loss...
|
|
OrthoLogic to Host Conference Call Discussing Year-End 2006 Results
Mar 7, 2007
|
10.6 KB |
| |
TEMPE, Ariz., March 7, 2007 (PRIME NEWSWIRE) -- OrthoLogic Corp. (Nasdaq:OLGC) announced today that it will release financial and operating results for the year ending December 31, 2006, on Wednesday, March 14, 2007.
Management will host a conference call and webcast the same day at 4:30 PM EDT (1:30 PM MT/PDT). The call may be acces...
|
|
OrthoLogic Announces Results of Post Hoc Subgroup Analysis of Data From Phase 3 Clinical Trial of Chrysalin (TP508) in Fracture Repair
Feb 16, 2007
|
14.3 KB |
| |
SAN DIEGO, Feb 16, 2007 (PrimeNewswire via COMTEX News Network) -- OrthoLogic Corp. (Nasdaq:OLGC) today announced findings of a post hoc subgroup analysis of data from its Phase 3 clinical trial of the novel synthetic peptide Chrysalin® (TP508) in unstable, displaced distal radius (wrist) fractures. Within the subset of female osteopenic su...
|
|
Phase 1/2 Clinical Trial Results to be Published Reporting Beneficial Effects of OrthoLogic's Chrysalin (TP508) in Treatment of Diabetic Foot Ulcers
Jan 25, 2007
|
14.7 KB |
| |
TEMPE, Ariz., Jan. 25, 2007 (PRIME NEWSWIRE) -- OrthoLogic Corp. (Nasdaq:OLGC) today announced that an article by Fife, et al entitled "Thrombin peptide Chrysalin® stimulates healing of diabetic foot ulcers in a placebo-controlled Phase I/II study" will appear in the January 2007 edition of Wound Repair and Regeneration. The randomized, ...
|
|
Studies of OrthoLogic's Chrysalin(R) (TP508) Show Specific Receptor Binding Activity and Effects in Human Endothelial Cells
Dec 11, 2006
|
14.6 KB |
| |
SAN DIEGO, Dec. 11 /PRNewswire-FirstCall/ -- OrthoLogic Corp.
(Nasdaq: OLGC) today announced results of experiments that advance the basic
science supporting its novel synthetic peptide Chrysalin (TP508). Two posters
are being presented at the American Society for Cell Biology 46th Annual
Meeting in San Diego, CA (December 9 - 13, 2006)...
|
|
OrthoLogic Announces Third Quarter 2006 Financial Results
Nov 2, 2006
|
17.3 KB |
| |
TEMPE, Ariz., Nov. 2 /PRNewswire-FirstCall/ -- OrthoLogic Corp.
(Nasdaq: OLGC) today announced financial results for the third quarter of
2006.
OrthoLogic reported a net loss of $5.8 million, or $0.14 per share, for
the third quarter of 2006, compared to a net loss of $7.6 million or $0.20 per
share, for the third quar...
|
|
|
